Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Privia Health Group, Inc.
Bear Case (25th pct.)
-75.5% vs price
Base Case (Median)
-74.3% vs price
Bull Case (75th pct.)
-65.8% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $2.49 | -87.7% | High (40%) |
| PE Comparable | $4.94 | -75.7% | Medium (25%) |
| Growth Trajectory DCF | $15.91 | -21.6% | Medium (20%) |
| Graham Number | $5.38 | -73.5% | Medium (40%) |
| EV/EBITDA | $7.46 | -63.3% | Medium (20%) |
| Earnings Power Value | $5.04 | -75.2% | Medium (50%) |
Based on 6 out of 7 methods, PRVA appears overvalued at the current price of $20.30. The base case fair value of $5.21 implies 74.3% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.